Entyvio Alternatives Compared
| Entyvio (vedolizumab) | Humira (adalimumab) | Stelara (ustekinumab) |
|
|---|
| Entyvio (vedolizumab) | Humira (adalimumab) | Stelara (ustekinumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
|
|||||||||||||||||||||||
| More about Entyvio (vedolizumab) | More about Humira (adalimumab) | More about Stelara (ustekinumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Entyvio has an average rating of 6.3 out of 10 from a total of 166 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 703 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Stelara has an average rating of 7.6 out of 10 from a total of 253 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 15% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Entyvio side effects |
View all Humira side effects |
View all Stelara side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Entyvio prices |
View all Humira prices |
View all Stelara prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other vedolizumab brands include: Entyvio Pen | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Starjemza, Steqeyma, Wezlana, Yesintek | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
600 hours |
480 hours |
1291.2 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 169 drugs are known to interact with Entyvio:
|
A total of 555 drugs are known to interact with Humira:
|
A total of 541 drugs are known to interact with Stelara:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 20, 2014 |
December 31, 2002 |
September 25, 2009 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Rinvoq
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...
Tremfya
Tremfya (guselkumab) injection is used to treat plaque psoriasis, psoriatic arthritis, ulcerative ...
Remicade
Remicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...
Azathioprine
Azathioprine is used for atopic dermatitis, autoimmune hepatitis, behcet's disease, bullous ...
Mesalamine
Mesalamine is used to treat mild to moderate ulcerative colitis and prevent the symptoms of ...
Budesonide
Oral budesonide is used to treat the following conditions with inflammation as a symptom ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.